CALCRL
Calcitonin gene-related peptide type 1 receptor
As of the edition of 20 October 2026, CALCRL (calcitonin gene-related peptide type 1 receptor, UniProt Q16602) has 10 drugs tested at it and 6 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16602
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 24
- Disease areas
- Nervous system; Ear, nose and throat; Eye; Lungs and airways; Cancer; Heart and blood vessels; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 178
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 5 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Erenumab | Marketed | Phase 4 | Ends 2030 |
| Rimegepant | Marketed | Phase 4 | Ends 2034 |
| Atogepant | Marketed | Phase 4 | Ends 2035 |
| Ubrogepant | Marketed | Phase 4 | Ends 2033 |
| Zavegepant | Marketed | Phase 4 | Ends 2034 |
| Telcagepant | Went quiet | Phase 3 | none listed |
| BI-44370 | Went quiet | Phase 2 | none listed |
| Olcegepant | Went quiet | Phase 2 | none listed |
| MK3207 | Went quiet | Phase 2 | none listed |
| Davalintide | Went quiet | Phase 2 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Merck & Co. | Route A |
| AstraZeneca | Route A |
The other 3 companies at CALCRL
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at CALCRL, ranked, with the facts behind eachRequest access. Nothing is shown until you do.